Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Appointed director
CC transcript
Inv. presentation
Director departure
|
|
INTERPACE BIOSCIENCES, INC. (IDXG)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
8-K
| Quarterly results |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/01/2023 |
8-K
| Quarterly results |
| 05/12/2023 |
8-K
| Quarterly results |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 03/27/2023 |
8-K
| Quarterly results |
| 03/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/15/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/04/2022 |
8-K
| Quarterly results |
| 10/04/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/20/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 09/20/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 09/09/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 09/07/2022 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Execution Version",
"Execution Version",
"Unaudited Pro Forma Condensed Consolidated Financial Information The unaudited pro forma condensed consolidated financial statements were prepared to assist readers in understanding the nature and effects of the sale by Interpace Biosciences, Inc., , on August 31, 2022 of substantially all of the assets and the ongoing business comprising the Company’ s Pharma Services business pursuant to the Asset Purchase Agreement, dated as of August 31, 2022, by and among Flagship Biosciences, Inc. , Interpace Pharma Solutions, Inc. and the Company . The unaudited pro forma condensed consolidated statements of operations for the six months ended June 30, 2022, and for the year ended December 31, 2021 have been prepared with the assumption that the Asset Sale was completed as of January 1, 2021. The Un..." |
|
| 08/15/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/16/2022 |
RW
| Form RW - Registration Withdrawal Request: |
| 05/16/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/16/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 04/29/2022 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
| 04/14/2022 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 03/31/2022 |
8-K
| Quarterly results|
Docs:
|
"INTERPACE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended Years Ended December 31, December 31, 2021 2020 2021 2020 Revenue, net $ 10,853 $ 9,646 $ 41,314 $ 32,398 Cost of revenue 6,404 6,517 23,369 21,673 Gross Profit 4,449 3,129 17,945 10,725 Sales and marketing 2,482 2,478 10,067 9,254 Research and development 407 673 1,882 2,795 General and administrative 4,030 5,508 13,669 18,192 Transition expenses 111 1,780 2,585 2,578 Loss on DiamiR transaction 248 - 13 - Acquisition amortization expense 728 1,115 4,064 4,461 Change in fair value of contingent consideration Total operating expenses 7,725 11,065 31,942 36,791 Operating loss Interest accretion expense Related party interest - - Other income, net 467 Loss from continuing operations before ta..." |
|
| 02/10/2022 |
SC 13G
| Singer Douglas Mark reports a 7% stake in Interpace Biosciences, Inc. |
| 02/01/2022 |
SC 13D/A
| Kamin Peter reports a 18.6% stake in Interpace Biosciences, Inc. |
| 01/28/2022 |
8-K
| Quarterly results |
| 01/27/2022 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 01/13/2022 |
SC 13D/A
| Kamin Peter reports a 18.6% stake in Interpace Biosciences, Inc. |
| 01/13/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/07/2022 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 01/03/2022 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
|
|
|